Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Fexofenadine HCL - Pseudoephedrine HCL Combination Versus Allegra in Patients With Seasonal Allergic Rhinitis
- Conditions
- Rhinitis Seasonal
- Interventions
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 520
- Registration Number
- NCT01306721
- Locations
- 🇯🇵
Investigational Site Number 392003, Osaka-Shi, Japan
🇯🇵Investigational Site Number 392001, Shinjuku-Ku, Japan
🇯🇵Investigational Site Number 392002, Koganei-Shi, Japan
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
- Conditions
- Locally Advanced or Metastatic Medullary Thyroid CancerMedullary Thyroid Cancer
- Interventions
- Behavioral: Patient outreach
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 205
- Registration Number
- NCT01298323
- Locations
- 🇦🇺
Investigational Site Number : 301, St Leonards, New South Wales, Australia
🇦🇹Investigational Site Number : 401, Wien, Austria
🇧🇪Investigational Site Number : 501, Anderlecht, Belgium
Study of Febrile Illness for Dengue-Endemic Areas in Latin America
- Conditions
- Dengue FeverFever
- First Posted Date
- 2011-02-10
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3000
- Registration Number
- NCT01293331
A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2011-02-10
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT01293630
- Locations
- 🇯🇵
Investigational Site Number 392002, Akashi-Shi, Japan
🇯🇵Investigational Site Number 392001, Hidaka-Shi, Japan
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2015-09-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 92
- Registration Number
- NCT01288469
- Locations
- 🇺🇸
Investigational Site Number 840619, Chicago, Illinois, United States
🇺🇸Investigational Site Number 840621, Richmond, Virginia, United States
🇺🇸Investigational Site Number 840602, Eugene, Oregon, United States
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2015-09-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 183
- Registration Number
- NCT01288443
- Locations
- 🇺🇸
Investigational Site Number 840525, Tempe, Arizona, United States
🇺🇸Investigational Site Number 840521, Bristol, Tennessee, United States
🇺🇸Investigational Site Number 840516, Los Angeles, California, United States
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer
- Conditions
- Lung Neoplasms
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 34
- Registration Number
- NCT01266512
- Locations
- 🇭🇰
Sanofi-Aventis Administrative Office, Hong Kong, Hong Kong
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
- Conditions
- Dementia Alzheimer's Type
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 291
- Registration Number
- NCT01266525
- Locations
- 🇺🇸
Investigational Site Number 840024, Costa Mesa, California, United States
🇺🇸Investigational Site Number 840041, Gilbert, Arizona, United States
🇵🇱Investigational Site Number 616004, Bydgoszcz, Poland
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: placebo
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 176
- Registration Number
- NCT01263886
- Locations
- 🇺🇸
Investigational Site Number 840009, Modesto, California, United States
🇨🇱Investigational Site Number 152003, Santiago, Chile
🇫🇷Investigational Site Number 250002, Dijon, France
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 984
- Registration Number
- NCT01254279
- Locations
- 🇮🇹
Investigational Site Number 380-005, Genova, Italy
🇦🇺Investigational Site Number 036002, Camperdown, Australia
🇦🇺Investigational Site Number 036020, Campbelltown, Australia